FDA Grants Expanded Access for HanchorBio's HCB101 to Oncology Patient

The FDA has approved HanchorBio's request for an Expanded Access Protocol for HCB101, an investigational immunotherapy. This allows a Phase 1 oncology patient, who showed clinical benefit, to continue receiving the treatment beyond the trial. This marks a notable instance of expanded access for a SIRPα Fc fusion protein in the U.S., offering continued hope for the patient.